Scoutpro Acs
FDA Clearance Information
The scoutpro acs was cleared through the FDA 510(k) pathway on July 23, 2010. It is manufactured by Biotronik and classified as a Class 2 medical device.
What It Is
FDA-Cleared Indications
- The FDA record identifies the device under product code DQY: percutaneous catheter, regulated under 21 CFR 870.1250.
- The supplied FDA indications field contains only “Statement” and does not specify a clinical indication.
Clinical Applications
- Use in a percutaneous catheter-based vascular procedure consistent with the device’s FDA-cleared labeling.
- Use by trained clinicians when the device’s official instructions for use identify the applicable anatomy, access route, and procedure.
Practical Considerations
- Confirm the current FDA clearance summary and manufacturer’s instructions for use before documenting the device as a venous stent.
- Do not assume that the device is indicated for deep vein thrombosis, chronic venous insufficiency, iliac-vein obstruction, or central-vein obstruction without verified labeling.
- Verify catheter dimensions, working length, compatibility with guidewires and accessory devices, and any vessel-size requirements in the instructions for use.
- MRI safety, including MR Safe, MR Conditional, or MR Unsafe status, cannot be determined from the supplied FDA record and should be confirmed in the manufacturer’s labeling.
- Review contraindications, warnings, deployment instructions, and storage requirements in the current manufacturer documentation.
Frequently Asked Questions
What is scoutpro acs used for?
The scoutpro acs is used to support veins in patients with venous obstructions, improving blood flow and reducing symptoms associated with conditions like deep vein thrombosis.
What specialties typically use this device?
Interventional radiologists and vascular surgeons typically use this device in both hospital and outpatient settings.
What are the FDA-cleared indications?
The scoutpro acs is indicated for use in patients with narrowed or blocked veins, such as those with deep vein thrombosis or chronic venous insufficiency.